Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities

About this update from Advicenne Sa

PARIS, September 19, 2025 --( BUSINESS WIRE )--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today reports its 2025 first half financial results, as approved on September 19, 2025 by the Board of Directors. The first half financial report is available on the Company’s website: www.advicenne.com . Didier Laurens, Chief Executive Officer of Advicenne, commented: "The first half of the fiscal year has been marked by the commitment of all Advicenne employees in preparation for the submission of the Sibnayal® marketing authorization application in the U.S. I am particularly proud of the work accomplished, and I am confident in our ability to submit the application during Q4 2025. I also note the strong growth in Sibnayal® sales in Europe and the Middle East, with the very recent announcement of marketing authorization in Saudi Arabia under favorable economic conditions. All these factors confirm the value of Sibnayal® for patients, their families, and the medical community. The coming months will be particularly important for Advicenne in achieving our value creation objectives." Highlights of 2025 Half-year financials Highlights of the 2025 half-year financial statements are presented in the table below. These come from the financial statements prepared in accordance with French accounting standards, which were approved by the Board of Directors. Since the publication of the 2024 annual results, Advicenne has been publishing its financial statements under French accounting standards. As the Company has not published consolidated accounts since the closure of its U.S. subsidiary in 2023, publication under IFRS standards is no longer relevant considering the statutory accounts of Advicenne SA. The audit work was performed by the Statutory Auditors who, after a limited review, did not identify any material misstatement or presentation issue. All financial statements and notes are available in the First Half Financial Report. Highlights of the first half of 2025 and post-period events In the United States, preparation of the marketing authorization application for Sibnayal® Continued commercial development of Sibnayal® in Europe and the Middle East Extension of financial visibility In July 2025, Advicenne finalized a debt restructuring and completed a capital increase of €2.6 million. These transactions extend the cash horizon to the fourth quarter of 2026. Outlook for the second half of 2025 Application for registration of ADV7103 in the U.S. The main objective is to submit the application for registration of ADV7103 in dRTA indication in the U.S during the fourth quarter. This will be a major step in creating value for the product and for Advicenne. Continued sales growth for Sibnayal®. During fiscal year 2025, Advicenne anticipates sales growth for its lead product, Sibnayal®, in Europe and the Middle East, in line with the trend observed in H1 2025. About Advicenne Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see : https://advicenne.com/ . Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on www.advicenne.com ) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements. 1 In France, where the price has not yet been contractually agreed with the authorities, taxes set by the regulatory authorities are paid to the collecting agencies. These taxes, calculated on the basis of gross sales, are recognized on the basis of the Company's best estimates or collection notices received from the authorities View source version on businesswire.com: https://www.businesswire.com/news/home/20250919691664/en/ Contacts Advicenne Didier Laurens, Directeur Général +33 (0) 1 87 44 40 17 Email: [email protected] Ulysse Communication Media relations Bruno Arabian +33 (0)6 87 88 47 26 Email: [email protected]

View stock analysis, news, and events for Advicenne Sa